Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Change in Cash (2016 - 2025)

Historic Change in Cash for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to -$20.8 million.

  • Regenxbio's Change in Cash fell 170801.39% to -$20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 3471.77%. This contributed to the annual value of $23.0 million for FY2024, which is 13684.77% up from last year.
  • As of Q3 2025, Regenxbio's Change in Cash stood at -$20.8 million, which was down 170801.39% from -$50.5 million recorded in Q2 2025.
  • Regenxbio's Change in Cash's 5-year high stood at $117.5 million during Q4 2021, with a 5-year trough of -$153.3 million in Q1 2022.
  • Moreover, its 5-year median value for Change in Cash was -$20.8 million (2025), whereas its average is -$14.7 million.
  • Its Change in Cash has fluctuated over the past 5 years, first tumbled by 4547669.9% in 2021, then skyrocketed by 39207.03% in 2024.
  • Quarter analysis of 5 years shows Regenxbio's Change in Cash stood at $117.5 million in 2021, then tumbled by 118.37% to -$21.6 million in 2022, then increased by 13.17% to -$18.7 million in 2023, then soared by 104.85% to $909000.0 in 2024, then tumbled by 2383.39% to -$20.8 million in 2025.
  • Its last three reported values are -$20.8 million in Q3 2025, -$50.5 million for Q2 2025, and $72.6 million during Q1 2025.